Boehringer Ingelheim
  • About Jardiance
  • About Metabolic
  • Resources
  • Contact
sa
Login

Metabolic

Metabolic

Metabolic

425
million adult people
in the world are living with diabetes, with Type 2 diabetes accounting for 90% of all cases1
 

Efficacy

Empagliflozin survival benefit

icoPDF

Empagliflozin survival benefit
EMPRISE Study; Effectiveness of Empagliflozin on reducing hospitalization for heart failure

icoPDF

EMPRISE Study; Effectiveness of Empagliflozin on reducing hospitalization for heart failure
EMPRISE Study; Empagliflozin real world effectiveness & Safety

icoPDF

EMPRISE Study; Empagliflozin real world effectiveness & Safety
EMPULSE Study; in-hospital intiation of Empagliflozin in patients hosptalized for HF with HFrEF or HFpEF, with or without T2D

icoPDF

EMPULSE Study; in-hospital intiation of Empagliflozin in patients hosptalized for HF with HFrEF or HFpEF, with or without T2D
EMPA-KIDNEY study; the study of heart and kidney protection with Empagliflozin in patients with CKD with or without T2D

icoPDF

EMPA-KIDNEY study; the study of heart and kidney protection with Empagliflozin in patients with CKD with or without T2D
EMPERIAL Studies; effects of Empagliflozin on functional capacity and quality of life in patients with chronic HFrEF or HFpEF with or without T2D

icoPDF

EMPERIAL Studies; effects of Empagliflozin on functional capacity and quality of life in patients with chronic HFrEF or HFpEF with or without T2D
EMPA-VISION Study; a mechanistic study to help explain how empagliflozin may improve HF-related outcomes

icoPDF

EMPA-VISION Study; a mechanistic study to help explain how empagliflozin may improve HF-related outcomes
EMPEROR Studies; two dedicated clinical outcomes studies of Empagliflozin for treating patients with HFrEF or HFpEF, with or without T2D

icoPDF

EMPEROR Studies; two dedicated clinical outcomes studies of Empagliflozin for treating patients with HFrEF or HFpEF, with or without T2D
EMPRISE Study; Empagliflozin real world comparative effictiveness & safety

06:35

EMPRISE Study; Empagliflozin real world comparative effictiveness & safety
EMPA-REG OUTCOME Trial; a true landmark trial and a real game changer

07:43

EMPA-REG OUTCOME Trial; a true landmark trial and a real game changer
Production date: Apr 2019
  • Therapeutic Area
  • Metabolic
  • Respiratory
  • Cardiovascular
  • Angels
  • Resources
  • Videos
  • Clinical studies
  • Site map
  • Terms of use
  • Privacy
  • Contact
  • Change country

© 2010-2021 Boehringer Ingelheim International GmbH. All rights reserved.